Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results
08 févr. 2023 07h12 HE
|
Purple Biotech Ltd.
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech...
Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
02 févr. 2023 07h00 HE
|
Purple Biotech Ltd.
Immunorizon’s lead compound targets 5T4 antigen and conditionally activates T cells and natural killer (NK) cells Conditional activation of T cells is designed to provide a wide therapeutic...
Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
03 janv. 2023 07h00 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
15 nov. 2022 07h00 HE
|
Purple Biotech Ltd.
Data demonstrate suppression by CM24 of NET-promoting cancer cell migration and metastasis Findings suggest potential new treatment target for metastasis REHOVOT, Israel, Nov. 15, 2022 ...
Purple Biotech to Present at the Jefferies London Healthcare Conference
10 nov. 2022 07h00 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class,...
Purple Biotech Reports Third Quarter 2022 Financial Results
08 nov. 2022 07h53 HE
|
Purple Biotech Ltd.
Well capitalized with cash runway through 2024 Clinical progress for both programs, CM24 and NT219 REHOVOT, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the...
Purple Biotech Appoints Lior Fhima as Chief Financial Officer
02 nov. 2022 07h37 HE
|
Purple Biotech Ltd.
Seasoned financial executive strengthens management team REHOVOT, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a...
Purple Biotech Reports Second Quarter 2022 Financial Results
04 août 2022 07h30 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Announces Executive Leadership Changes
14 juil. 2022 07h30 HE
|
Purple Biotech Ltd.
Gil Efron appointed as Chief Executive Officer Isaac Israel to transition to advisor role, continue as Board member REHOVOT, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd....
Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile
27 mai 2022 07h15 HE
|
Purple Biotech Ltd.
A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer REHOVOT, Israel, May 27, 2022 (GLOBE NEWSWIRE) --...